A
13.39
0.59 (4.61%)
| Previous Close | 12.80 |
| Open | 12.94 |
| Volume | 356,419 |
| Avg. Volume (3M) | 1,645,569 |
| Market Cap | 415,978,240 |
| Price / Book | 3.86 |
| 52 Weeks Range | |
| Earnings Date | 12 Nov 2025 |
| Diluted EPS (TTM) | -2.30 |
| Total Debt/Equity (MRQ) | 19.01% |
| Current Ratio (MRQ) | 22.53 |
| Operating Cash Flow (TTM) | -53.00 M |
| Levered Free Cash Flow (TTM) | -39.36 M |
| Return on Assets (TTM) | -22.88% |
| Return on Equity (TTM) | -38.04% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Alto Neuroscience, Inc. | Bullish | Bullish |
AIStockmoo Score
0.5
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | 0.5 |
| Average | 0.50 |
|
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals’ neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 7.48% |
| % Held by Institutions | 77.52% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Alpha Wave Global, Lp | 30 Sep 2025 | 3,707,757 |
| Armistice Capital, Llc | 30 Sep 2025 | 1,636,000 |
| Vestal Point Capital, Lp | 30 Sep 2025 | 950,000 |
| 72 Investment Holdings, Llc | 30 Sep 2025 | 667,778 |
| Alkeon Capital Management Llc | 30 Sep 2025 | 477,101 |
| Integral Health Asset Management, Llc | 30 Sep 2025 | 400,000 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 50.00 (HC Wainwright & Co., 273.41%) | Buy |
| Median | 25.00 (86.71%) | |
| Low | 15.00 (Chardan Capital, 12.02%) | Buy |
| Average | 27.80 (107.62%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 10.87 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| BTIG | 17 Nov 2025 | 27.00 (101.64%) | Buy | 13.80 |
| Baird | 13 Nov 2025 | 22.00 (64.30%) | Buy | 11.35 |
| 20 Oct 2025 | 16.00 (19.49%) | Buy | 11.00 | |
| Jefferies | 12 Nov 2025 | 25.00 (86.71%) | Buy | 14.20 |
| HC Wainwright & Co. | 24 Oct 2025 | 50.00 (273.41%) | Buy | 11.00 |
| Chardan Capital | 29 Sep 2025 | 15.00 (12.02%) | Buy | 4.01 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |